SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future treatment of Nontuberculous Mycobacterial (NTM) pulmonary diseases and Pseudomonas aeruginosa (PsA) pulmonary infections.
MRX-5, a novel benzoxaborole antibiotic, is developed for the treatment of rare chronic pulmonary disease caused by NTM infection. MRX-5 exhibits excellent antibacterial activity against common NTM pathogens and demonstrates good safety in animal trials.MABC affects approximately 12,000 to 20,000 patients in the US and requires treatment durations exceeding 12 months. MRX-5 holds promise for addressing NTM infections.
MRX-8, a novel antibiotic in the polymyxin class, is designed to treat severe infections caused by multidrug-resistant Gram-negative bacteria. Traditional polymyxins are limited in clinical use due to high risks of nephrotoxicity and neurotoxicity. MRX-8, with its novel chemical structure, maintains or improves therapeutic efficacy while significantly reducing these risks.
The company also aims to explore the clinical and commercial potential of developing an inhaled formulation targeting chronic lung infections. In mouse models of PsA lung infections, nebulized MRX-8 demonstrated significant reduction in bacterial load in lung tissues, indicating strong bactericidal activity.
At the forum, Dr. Regis Vilchez focused on presenting the development progress and future plans for MRX-5 and MRX-8, while analyzing the significant market demand for treatments targeting NTM lung disease and chronic PsA pulmonary infections. These two pipeline products are expected to fill gaps in the treatment of NTM lung disease and chronic PsA pulmonary infections, offering patients safer and more effective new treatment options.
MicuRx Pharmaceuticals remains committed to discovering, developing, and commercializing innovative medicines to meet unmet clinical needs, providing patients with differentiated therapeutic solutions. The company will continue to actively advance the development of MRX-5 and MRX-8, aiming to bring these innovative drugs to market as soon as possible, bringing hope to patients worldwide.
For more information, please contact:
MicuRx Pharmaceuticals, Inc.
Website: www.micurx.com
About MicuRx Pharmaceuticals
MicuRx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibiotics for the treatment of multidrug-resistant infections. With a mission to address significant unmet medical needs, MicuRx is advancing a portfolio of drug candidates targeting difficult-to-treat infections.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum
Podium on AI Simulation Recognized as 'Top 5 Applied Research' at This Year's Congress
AI-Powered Skin Diagnostic System and Plant-Based PDRN Research Presented in Poster Sessions
SEOUL, South Korea, Oct. 18, 2024 /PRNewswire/ -- Amorepacific presented its latest research at this year's International Federation of Societies of Cosmetic Chemists conference (34th Congress IFSCC BRAZIL) held in Foz do Iguaçu, Brazil, from October 14 to 17.
Amorepacific R&I Center scientists showcased diverse research and innovative technologies, including Lee Jeong Yu's podium presentation, 'Artificial Tactile Sensory System and High-Precision AI Simulation for Cosmetic Products,' which was selected as 2024 IFSCC 'Top 5 Applied Research.'
The AI simulation research focuses on Amorepacific's artificial intelligence sensory evaluation system, 'SensornoidTM.' With digital sensory data from SensornoidTM, it is possible to predict the usage experience of the final cosmetic products solely based on ingredient formulation data. This technology integrates Amorepacific's long-standing human-based cosmetic evaluation research expertise with digital technology. Utilizing this simulation significantly reduces the time and cost associated with traditional sensory research reliant on human perception, enabling faster and more effective product development. Additionally, by meticulously designing formulation simulations, the system can predict the sensory experience of cosmetics with over 90% accuracy compared to human application tests.
In addition, Amorepacific showcased two poster presentations. With a poster titled 'Innovative AI-Powered Visual Insights for Understanding Facial Skin Aging,' Amorepacific's R&I Center's Park Hyeokgon introduced the new visual analysis of the AI-based skin diagnostic system 'Dr. AMORE.' This technology precisely analyzes and visualizes various signs of facial skin aging, enabling the tracking and analysis of the integrated and dynamic skin aging process. These findings are expected to contribute to the provision of advanced anti-aging solutions.
Another poster, 'Sustainable and Vegan BluePDRN (PolyDeoxyRiboNucleotide) Purified from Microalgae,' by Amorepacific's R&I Center Researcher Kim Hyuk, presented research on the extraction of plant-based PDRN (BluePDRN) with high purity from microalgae. PDRN, recognized for its wound healing and anti-inflammatory effects in numerous studies, is widely used in cosmetic procedures and skincare products. Through research on extracting high-purity plant-based PDRN, Amorepacific confirmed the potential for the sustainable vegan cosmetics ingredient.
Suh Byung-fhy, the CTO of Amorepacific and Director of its R&I Center stated, "Presenting Amorepacific's diverse research and innovative technologies at the IFSCC and being selected for outstanding research has been highly meaningful." He added, "Based on the various technologies presented this time, Amorepacific will continue to strive to offer the finest products to customers around the globe."
The International Federation of Societies of Cosmetic Chemists is the world's largest cosmetic conference. Established in 1959 to promote international technological exchange and collaboration among cosmetic researchers, this year's event was themed 'Biodiversity and Cosmetics: Science for Reaching a Sustainable Technology.'
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Amorepacific Presents Latest Research at IFSCC
